ICON Announces the Expansion of its Accellacare Site Network
ICON plc, a global provider of drug development and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations, today announced that its Accellacare Site Network has expanded in reach and capabilities through new partnerships with six research sites across four countries.
Agreements with Asclepes Research and Olympian Clinical Research in the US, Curiositas ad Sanum and Intermed in Germany, Quironsalud in Spain, and KO-MED in Poland brings the Accellacare network to 112 active locations across eight countries and the entry to two new US states–Florida and California. Through these new partnerships, Accellacare is also enhancing its capability in the central nervous system (CNS) and immune-inflammation therapeutic areas.
Read more about the new partnerships here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
